SELDI-TOF-MS技术在弥漫性大B细胞淋巴瘤诊断中的意义  

Application of SELDI-TOF-MS technique and its significance in diffuse large B-cell lymphoma

作　　者：王晋芬[1] 李义[2] 杨瑞红[1] 王国平[1] 郗彦凤[1] 

机构地区：[1]山西省肿瘤医院病理科,太原030013 [2]山西医科大学

出　　处：《诊断病理学杂志》2009年第6期409-412,共4页Chinese Journal of Diagnostic Pathology

基　　金：山西省自然科学基金资助项目(编号2007011127);山西省科技攻关项目(编号20080311062-2);山西省留学人员重点科研资助项目(编号2008-10-5)

摘　　要：目的应用表面增强激光解析电离飞行时间质谱(SELDI-TOF-MS)技术从弥漫性大B细胞淋巴瘤(DLBCL)石蜡标本中筛选差异蛋白,并检测生发中心型(GCB型)与非生发中心型(non-GCB型)弥漫性大B细胞淋巴瘤之间的差异蛋白。方法运用免疫组化方法检测41例DLBCL中CD3、CD20、CD10、bcl-6和MUM-1的表达,依据Hans分类方法将DLBCL分为预后有显著差异的两种亚型:GCB型和non-GCB型。选用WCX2芯片及SELDI-TOF-MS技术对这两组亚型的石蜡标本进行蛋白指纹图谱检测并比较其不同。15例淋巴结反应性增生的石蜡组织标本作为对照。用Biomarker Wizard软件对数据进行分析。结果在质荷比位于2～20kDa的范围内,以波峰的信噪比(S/N)>5为标准,经软件分析发现DLBCL与淋巴结反应性增生之间共有6个蛋白波峰强度值存在明显差异(P<0.05)。GCB型与non-GCB型DLBCL中共有2个蛋白波峰强度值存在明显差异(P<0.05)。结论免疫组化与SELDI蛋白芯片技术相结合可检测DLBCL患者的特异性标记物,差异蛋白可能有助于DLBCL的诊断。Objective Surface enhanced laser desorption/ionization time of flight mass spectrometry （SELDI-TOF-MS） technique was employed to detect the protein biomarkers in diffuse large B-cell lymphomas （CLBCLs） from paraffln-embedded tissues. The technique was also used to explore different protein biomarkers between germinal center B-cell hke （GCB） and nongerminal center B-cell like （non-GCB） types of DLBCLs. Methods 41 cases of DLBCLs were selected to do the immunohistochemistry with a panel of antibodies CD3, CD10, CD20, bcl-6 and MUM-1. The DLBCLs were classified into GCB and uon-GCB phenotype according to Hans＇ algorithm. SELDI technique （WCX2 proteinchips） was used to detect the paraffinembedded tissue of DLBCLs. 15 cases of reactive hyperplasia of lymph node were used as control. The data were analyzed by Biomarker Wizard solftware. Results In the m/z range of 2-20 kDa, as the peak＇ s S/N 〉 5, 6 different proteins （ 8 584, 8 711, 10 134, 4 287, 2 031, and 2 011 Da） were found between DLBCL and reactive hyperplasia of lymph node （ P 〈 0.05）. 2 different proteins （2 153 Da, 3 156 Da） were detected between GCB and nonGCB-DLBCL （ P 〈 0.05）. Conclusions The specific biomarkers of DLBCL could be detected by using immunohistochemical method and SELDI proteinehip technology, which might be help in the lymphoma diagnosis and evaluation of the prognosis. The proteins 8 584, 8 711, 10 134, 4 287, 2 031, and 2011 Da might be useful in the diagnosis of DLBCL. The proteins 2 153 Da and 3 156Da might have significance in the classification of DLBCL.

关 键 词：DLBCL 分子亚型 SELDI—TOF—MS 蛋白组学 免疫组化 预后 

分 类 号：R733.7[医药卫生—肿瘤]